Fischer Medical Ventures has approved an aggregate investment of ₹50 crore to participate in the rights issues of three of its wholly owned material subsidiaries. The board decision, taken on September 24, 2026, strengthens the capital base of entities operating in medical imaging, digital healthcare, and global medical device distribution.

Investment breakdown by subsidiary

The company will subscribe to equity shares offered by Time Medical International Ventures (India) Private Limited, FlynnCare Health Innovations Private Limited, and FMV Global Innovation Pte. Ltd. The allocation reflects the specific capital requirements and valuation of each entity.

Subsidiary profiles and financials

Time Medical International Ventures (India) Private Limited operates in the medical diagnostic imaging sector, manufacturing MRI systems at its Visakhapatnam facility. The company reported a turnover of ₹5,500.50 lakh for FY26, down from ₹8,273.58 lakh in FY25.

FlynnCare Health Innovations Private Limited focuses on digital healthcare solutions, including a Digital Hospital platform and community care services. Incorporated in July 2024, it recorded a turnover of ₹8,629.26 lakh in FY26, a significant increase from ₹2,742.46 lakh in FY25.

FMV Global Innovation Pte. Ltd., incorporated in Singapore in July 2024, handles wholesale marketing and sale of medical devices globally. It reported a turnover of S$22,808,941 for FY26, with no revenue in FY25.

Regulatory and transaction details

All three entities are classified as material unlisted subsidiaries under Regulation 24(1) of SEBI (LODR) Regulations, 2015. The transactions are related party deals conducted at arm's length, supported by valuation reports from registered valuers. The consideration is entirely cash-based.

What the numbers show

The investment distribution reveals a strategic tilt toward FMV Global Innovation, which receives ₹26 crore, or 52% of the total capital deployed. This is notable given that FMV Global was incorporated only in FY25 and generated S$22.8 million in turnover in its first full year of operations (FY26). In contrast, Time Medical, despite having a longer operational history since 2019 and higher cumulative revenue, receives the smallest share at ₹11.5 crore. This suggests Fischer Medical Ventures is prioritizing the rapid scaling of its international distribution arm over stabilizing its domestic imaging manufacturing unit.

Fischer Medical Ventures Limited submitted a revised investor and strategic partnership presentation to stock exchanges on September 17, 2026. The filing updates materials from an investor and analyst call held on September 7, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company positions itself as an integrated AI-enabled healthcare platform. Its ecosystem spans medical imaging, population-scale screening, hospital digitization, and analytics. Operations cover India, the US, Hong Kong, MENA, and SEA.

Strategic Ecosystem

Fischer Medical Ventures operates through three core brands. Time Medical provides the technology foundation with advanced MRI and diagnostic equipment. FlynnCare Health Innovations develops AI healthcare applications and the MIDAS screening ecosystem. Fischer Medical Ventures serves as the commercialization and capital vehicle.

Imaging Portfolio

The company’s diagnostic range includes MRI systems from 0.35T to 7.0T. Key products include the PICA and AURA open architecture systems, and the MICA, QUIN, and NEXA closed-bore platforms. The portfolio also features CT scanners, portable X-ray machines, and mammography solutions.

AI and Digital Health

FlynnCare’s MIDAS platform consolidates ten screening modules including eye, oral, mental, and cardiovascular health. The LIVE Dx platform enables population-scale screening with tele-health integration. Clinics 2.0 offers EHR, HIS, and practice management tools.

What the Numbers Show

The presentation highlights a vertically integrated model. The company controls the stack from proprietary magnet technology in hardware to AI analytics in software. This structure aims to create a single patient record across device, data, and decision layers.